Claims

1. A method for manufacturing a tablet, which comprises the steps of
   (A) filling a starting material, which is in a solid form, in a first open cavity, which is formed by a first punch and a die, to obtain a second open cavity, which is filled at least partly with the starting material,
   (B) closing the second open cavity by a second punch to obtain a first closed cavity,
   (C) compressing the starting material at a compression temperature below 37°C by moving at least one out of the first punch and the second punch to obtain a second closed cavity, which has a smaller volume than the first closed cavity, which results in formation of a trapped tablet of the starting material in the second closed cavity,
   (D) removing the trapped tablet to obtain the tablet, which has a tablet temperature below 37°C directly after removal,

   wherein the steps (A), (B), (C) and (D) are conducted in a tablet press,

   wherein the starting material is solid at 37 °C and 101.32 KPa and consists out of
   (i) 60 to 100 wt.% of a first polymer stabilizer, which is
      (i-1) tris(2,4-ditert-butylphenyl) phosphite (CAS-No. 31570-04-4),
      (i-2) bis(2,4-dicumylphenyl) pentaerythritol diphosphite (CAS-No. 154862-43-8),
      (i-3) bis(2,4-ditert-butylphenyl)pentaerythritol diphosphite (CAS-No. 26741-53-7),
      (i-4) tetrakis-[3-(3,5-ditert-butyl-4-hydroxy-phenyl)-propionyloxymethyl]methane (CAS-No. 6683-19-8),
      (i-5) 3-(3,5-ditert-butyl-4-hydroxy-phenyl)-propionic acid stearyl ester (CAS-No. 2082-79-3),
      (i-6) 3-(3,5-ditert-butyl-4-hydroxy-phenyl)-N-[6-[3-(3,5-ditert-butyl-4-hydroxy-phenyl)propanoylamino]hexyl]propanamide (CAS-No. 23128-74-7),
      (i-7) 3-(3,5-ditert-butyl-4-hydroxyphenyl)-N'-[3-(3,5-ditert-butyl-4-hydroxyphenyl)-propanoyl]propanehydrazide (CAS-No. 3268-78-8),
      (i-8) 2-[2-[2-[3-(3-tert-butyl-4-hydroxy-5-methyl-phenyl)propanoyloxy]ethoxy]ethoxy]ethyl 3-(3-tert-butyl-4-hydroxy-5-methyl-phenyl)propanoate (CAS-No. 36443-68-2),
      (i-9) 4-[[3,5-bis[(3,5-ditert-butyl-4-hydroxy-phenyl)methyl]-2,4,6-trimethyl-phenyl]methyl]-2,6-ditert-butyl-phenol (CAS-No. 1709-70-2),
      (i-10) 1,3,5-tris(3,5-ditert-butyl-4-hydroxybenzyl)-1,3,5-triazine-2,4,6(1H,3H,5H)-trione (CAS-No. 27676-62-6),
      (i-11) bis[3,3-bis(4'-hydroxy-3'-tert-butylphenyl) butanoic acid] glycol ester (CAS-No. 32509-66-3),
      (i-12) N,N-dioctadecylhydroxylamine (CAS-No. 123250-74-8),
      (i-13) dodecyl 3-(3-dodecoxy-3-oxo-propyl)sulfanylpropanoate (CAS-No. 123-28-4),
      (i-14) octadecyl 3-(3-octadecoxy-3-oxo-propyl)sulfanylpropanoate (CAS-No. 693-36-7),

(i-15) pentaerythritol tetrakis[3-dodecylthio proprionate] (CAS-No. 29598-76-3),
(i-16) bis(2,2,6,6-tetramethyl-4-piperidyl) decanedioate (CAS-No.52829-07-9),
(i-17) (2-hydroxy-4-octoxy-phenyl)-phenyl-methanone (CAS-No. 1843-05-6),
(i-18) 2-tert-butyl-6-(5-chlorobenzotriazol-2-yl)-4-methyl-phenol (CAS-No. 3896-11-5),
(i-19) 2-(4,6-diphenyl-1,3,5-triazin-2-yl)-5-hexoxy-phenol (CAS-No. 147315-50-2),
(i-20) 2-[4,6-bis(4-phenylphenyl)-1,3,5-triazin-2-yl]-5-(2-ethylhexoxy)phenol (CAS-No. 204583-39-1),
(i-21) 2-[4,6-bis(2,4-dimethylphenyl)-1,3,5-triazin-2-yl]-5-[3-(2-ethylhexoxy)-2-hydroxy-propoxy]phenol (CAS-No. 137658-79-8),
(i-22) butanedioic acid, 1,4-dimethyl ester, polymer with 4-hydroxy-2,2,6,6-tetramethyl-1-piperidineethanol (CAS-No. 65447-77-0),
(i-23) N,N',N'',N'''-tetrakis-(2,4-bis[N-(1-cyclohexyloxy-2,2,6,6-tetramethylpiperidin-4-yl)-butylamino]-1,3,5-triazin-6-yl)-1,5,8,12-tetrazadodecane (CAS-No. 122587-07-9),
(i-24) N,N',N'',N'''-Tetrakis-(2,4-bis[N-(1-cyclohexyloxy-2,2,6,6-tetramethylpiperidin-4-yl)-butylamino]-1,3,5-triazin-6-yl)-1,5,8,12-tetrazadodecane (CAS-No. 106990-43-6),
(i-25) N,N'-bis-(2,4-bis[N-(1-propoxy-2,2,6,6-tetramethylpiperidin-4-yl)-butylamino]-1,3,5-triazin-6-yl)-N,N'-bis[N-(1-propoxy-2,2,6,6-tetramethylpiperidin-4-yl)]-1,8-diazaoctane (CAS-No. 1271737-36-0),
(i-26) poly[[6-[butyl(2,2,6,6-tetramethyl-4-piperidinyl)amino]-1,3,5-triazine-2,4-diyl][(2,2,6,6-tetramethyl-4-piperidinyl)imino]-1,6-hexanediyl[(2,2,6,6-tetramethyl-4-piperidinyl)imino]], α-[[6-[[4,6-bis(dibutylamino)-1,3,5-triazin-2-yl](2,2,6,6-tetramethyl-4-piperidinyl)amino]hexyl](2,2,6,6-tetramethyl-4-piperidinyl)amino]-ω-[4,6-bis(dibutylamino)-1,3,5-triazin-2-yl]- (CAS-No. 195300-91-5),
(i-27) poly[[6-[butyl(2,2,6,6-tetramethyl-1-propoxy-4-piperidinyl)amino]-1,3,5-triazine-2,4-diyl][(2,2,6,6-tetramethyl-1-propoxy-4-piperidinyl)imino]-1,6-hexanediyl[(2,2,6,6-tetramethyl-1-propoxy-4-piperidinyl)imino]], α-[[6-[[4,6-bis(dibutylamino)-1,3,5-triazin-2-yl](2,2,6,6-tetramethyl-1-propoxy-4-piperidinyl)amino]hexyl](2,2,6,6-tetramethyl-1-propoxy-4-piperidinyl)amino]-ω-[4,6-bis(dibutylamino)-1,3,5-triazin-2-yl]- (CAS-No. 297748-93-7),
(i-28) poly[[6-[(1,1,3,3-tetramethylbutyl)amino]-1,3,5-triazine-2,4-diyl][(2,2,6,6-tetramethyl-4-piperidinyl)imino]-1,6-hexanediyl[(2,2,6,6-tetramethyl-4-piperidinyl)imino]] (CAS-No. 71878-19-8),
(i-29) tetrakis(1,2,2,6,6-pentamethyl-4-piperidyl) butane-1,2,3,4-tetracarboxylate (CAS-No. 91788-83-9),
or a mixture thereof,

(ii) 0 to 40 wt.% of a second polymer stabilizer, which is zinc stearate, calcium stearate, magnesium stearate or a mixture thereof,

(iii) 0 to 34 wt.% of a third polymer stabilizer, which is zinc oxide, hydrotalcite, sodium benzoate or a mixture thereof,

(iv) 0 to 20 wt.% of a further ingredient, which is different to the first polymer stabilizer, the second polymer stabilizer and the third polymer stabilizer,

wherein the sum of components (i), (ii), (iii) and (iv) is 100 wt.%,

wherein the tablet has a weight above 20 mg and below 330 mg and a cross-section dimension above 3 mm and below 18 mm.

2. A method for manufacturing a tablet according to claim 1, wherein the first polymer stabilizer is

(i-1) tris(2,4-ditert-butylphenyl) phosphite (CAS-No. 31570-04-4),

(i-4) tetrakis-[3-(3,5-ditert-butyl-4-hydroxy-phenyl)-propionyloxymethyl]methane (CAS-No. 6683-19-8),

(i-5) 3-(3,5-ditert-butyl-4-hydroxy-phenyl)-propionic acid stearyl ester (CAS-No. 2082-79-3),

(i-6) 3-(3,5-ditert-butyl-4-hydroxy-phenyl)-N-[6-[3-(3,5-ditert-butyl-4-hydroxy-phenyl)propanoylamino]hexyl]propanamide (CAS-No. 23128-74-7),

(i-7) 3-(3,5-ditert-butyl-4-hydroxyphenyl)-N'-[3-(3,5-ditert-butyl-4-hydroxyphenyl)-propanoyl]propanehydrazide (CAS-No. 32687-78-8),

(i-8) 2-[2-[2-[3-(3-tert-butyl-4-hydroxy-5-methyl-phenyl)propanoyloxy]ethoxy]ethoxy]ethyl 3-(3-tert-butyl-4-hydroxy-5-methyl-phenyl)propanoate (CAS-No. 36443-68-2),

(i-9) 4-[[3,5-bis[(3,5-ditert-butyl-4-hydroxy-phenyl)methyl]-2,4,6-trimethyl-phenyl]methyl]-2,6-ditert-butyl-phenol (CAS-No. 1709-70-2),

(i-10) 1,3,5-tris(3,5-ditert-butyl-4-hydroxybenzyl)-1,3,5-triazine-2,4,6(1H,3H,5H)-trione (CAS-No. 27676-62-6),

(i-12) N,N-dioctadecylhydroxylamine (CAS-No. 123250-74-8)

(i-13) dodecyl 3-(3-dodecoxy-3-oxo-propyl)sulfanylpropanoate (CAS-No. 123-28-4),

(i-14) octadecyl 3-(3-octadecoxy-3-oxo-propyl)sulfanylpropanoate (CAS-No. 693-36-7),

(i-16) bis(2,2,6,6-tetramethyl-4-piperidyl) decanedioate (CAS-No.52829-07-9),

or a mixture thereof.

3. A method for manufacturing a tablet according to claim 2, wherein the first polymer stabilizer is

(i-1) tris(2,4-ditert-butylphenyl) phosphite (CAS-No. 31570-04-4),

(i-4) tetrakis-[3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-propionyloxymethyl]methane (CAS-No. 6683-19-8),

(i-5) 3-(3,5-ditert-butyl-4-hydroxy-phenyl)-propionic acid stearyl ester (CAS-No. 2082-79-3),

(i-7) 3-(3,5-ditert-butyl-4-hydroxyphenyl)-N'-[3-(3,5-ditert-butyl-4-hydroxyphenyl)-propanoyl]propanehydrazide (CAS-No. 32687-78-8),

(i-10) 1,3,5-tris(3,5-di-tert-butyl-4-hydroxybenzyl)-1,3,5-triazine-2,4,6(1H,3H,5H)-trione (CAS-No. 27676-62-6),

(i-16) bis(2,2,6,6-tetramethyl-4-piperidyl) decanedioate (CAS-No.52829-07-9),
or a mixture thereof.

4. A method for manufacturing a tablet according to any precedent claim, wherein the starting material has a mean particle size above 15 µm and below 1000 µm as determined by light scattering.

5. A method for manufacturing a tablet according to any precedent claim, wherein the starting material has a bulk density above 300 g / L and below 950 g / L as determined by DIN EN ISO 17892-3.

6. A method for manufacturing a tablet according to any precedent claim, wherein the compressing at step (C) takes place with a compression pressure above 90 MPa and below 600 MPa.

7. A method for manufacturing a tablet according to any precedent claim, wherein the compression temperature is below 32 °C and the tablet temperature is below 32 °C.

8. A method for manufacturing a tablet according to any precedent claim, wherein the tablet press is an eccentric tablet press or a rotary tablet press.

9. A tablet, which is solid at 37 °C and 101.32 KPa and consists out of
(i) 60 to 100 wt.% of a first polymer stabilizer, which is
(i-1) tris(2,4-ditert-butylphenyl) phosphite (CAS-No. 31570-04-4),
(i-2) bis(2,4-dicumylphenyl) pentaerythritol diphosphite (CAS-No. 154862-43-8),
(i-3) bis(2,4-ditert-butylphenyl)pentaerythritol diphosphite (CAS-No. 26741-53-7),
(i-4) tetrakis-[3-(3,5-ditert-butyl-4-hydroxy-phenyl)-propionyloxymethyl]methane (CAS-No. 6683-19-8),
(i-5) 3-(3,5-ditert-butyl-4-hydroxy-phenyl)-propionic acid stearyl ester (CAS-No. 2082-79-3),
(i-6) 3-(3,5-ditert-butyl-4-hydroxy-phenyl)-N-[6-[3-(3,5-ditert-butyl-4-hydroxy-phenyl)propanoylamino]hexyl]propanamide (CAS-No. 23128-74-7),
(i-7) 3-(3,5-ditert-butyl-4-hydroxyphenyl)-N'-[3-(3,5-ditert-butyl-4-hydroxyphenyl)-propanoyl]propanehydrazide (CAS-No. 3268-78-8),
(i-8) 2-[2-[2-[3-(3-tert-butyl-4-hydroxy-5-methyl-phenyl)propanoyloxy]ethoxy]ethoxy]ethyl 3-(3-tert-butyl-4-hydroxy-5-methyl-phenyl)propanoate (CAS-No. 36443-68-2),
(i-9) 4-[[3,5-bis[(3,5-ditert-butyl-4-hydroxy-phenyl)methyl]-2,4,6-trimethyl-phenyl]methyl]-2,6-ditert-butyl-phenol (CAS-No. 1709-70-2),
(i-10) 1,3,5-tris(3,5-ditert-butyl-4-hydroxybenzyl)-1,3,5-triazine-2,4,6(1H,3H,5H)-trione (CAS-No. 27676-62-6),

(i-11) bis[3,3-bis(4'-hydroxy-3'-tert-butylphenyl) butanoic acid] glycol ester (CAS-No. 32509-66-3),

(i-12) N,N-dioctadecylhydroxylamine (CAS-No. 123250-74-8),

(i-13) dodecyl 3-(3-dodecoxy-3-oxo-propyl)sulfanylpropanoate (CAS-No. 123-28-4),

(i-14) octadecyl 3-(3-octadecoxy-3-oxo-propyl)sulfanylpropanoate (CAS-No. 693-36-7),

(i-15) pentaerythritol tetrakis[3-dodecylthio proprionate] (CAS-No. 29598-76-3),

(i-16) bis(2,2,6,6-tetramethyl-4-piperidyl) decanedioate (CAS-No.52829-07-9),

(i-17) (2-hydroxy-4-octoxy-phenyl)-phenyl-methanone (CAS-No. 1843-05-6),

(i-18) 2-tert-butyl-6-(5-chlorobenzotriazol-2-yl)-4-methyl-phenol (CAS-No. 3896-11-5),

(i-19) 2-(4,6-diphenyl-1,3,5-triazin-2-yl)-5-hexoxy-phenol (CAS-No. 147315-50-2),

(i-20) 2-[4,6-bis(4-phenylphenyl)-1,3,5-triazin-2-yl]-5-(2-ethylhexoxy)phenol (CAS-No. 204583-39-1),

(i-21) 2-[4,6-bis(2,4-dimethylphenyl)-1,3,5-triazin-2-yl]-5-[3-(2-ethylhexoxy)-2-hydroxy-propoxy]phenol (CAS-No. 137658-79-8),

(i-22) butanedioic acid, 1,4-dimethyl ester, polymer with 4-hydroxy-2,2,6,6-tetramethyl-1-piperidineethanol (CAS-No. 65447-77-0),

(i-23) N,N',N'',N'''-tetrakis-(2,4-bis[N-(1-cyclohexyloxy-2,2,6,6-tetramethylpiperidin-4-yl)-butylamino]-1,3,5-triazin-6-yl)-1,5,8,12-tetrazadodecane (CAS-No. 122587-07-9),

(i-24) N,N',N'',N'''-Tetrakis-(2,4-bis[N-(1-cyclohexyloxy-2,2,6,6-tetramethylpiperidin-4-yl)-butylamino]-1,3,5-triazin-6-yl)-1,5,8,12-tetrazadodecane (CAS-No. 106990-43-6),

(i-25) N,N'-bis-(2,4-bis[N-(1-propoxy-2,2,6,6-tetramethylpiperidin-4-yl)-butylamino]-1,3,5-triazin-6-yl)-N,N'-bis[N-(1-propoxy-2,2,6,6-tetramethylpiperidin-4-yl)]-1,8-diazaoctane (CAS-No. 1271737-36-0),

(i-26) poly[[6-[butyl(2,2,6,6-tetramethyl-4-piperidinyl)amino]-1,3,5-triazine-2,4-diyl][(2,2,6,6-tetramethyl-4-piperidinyl)imino]-1,6-hexanediyl[(2,2,6,6-tetramethyl-4-piperidinyl)imino]], α-[[6-[[4,6-bis(dibutylamino)-1,3,5-triazin-2-yl](2,2,6,6-tetramethyl-4-piperidinyl)amino]hexyl](2,2,6,6-tetramethyl-4-piperidinyl) amino]-ω-[4,6-bis(dibutylamino)-1,3,5-triazin-2-yl]- (CAS-No. 195300-91-5),

(i-27) poly[[6-[butyl(2,2,6,6-tetramethyl-1-propoxy-4-piperidinyl)amino]-1,3,5-triazine-2,4-diyl][(2,2,6,6-tetramethyl-1-propoxy-4-piperidinyl)imino]-1,6-hexanediyl[(2,2,6,6-tetramethyl-1-propoxy-4-piperidinyl)imino]], α-[[6-[[4,6-bis(dibutylamino)-1,3,5-triazin-2-yl](2,2,6,6-tetramethyl-1-propoxy-4-piperidinyl)amino]hexyl](2,2,6,6-tetramethyl-1-propoxy-4-piperidinyl)amino]-ω-[4,6-bis(dibutylamino)-1,3,5-triazin-2-yl]- (CAS-No. 297748-93-7),

(i-28) poly[[6-[(1,1,3,3-tetramethylbutyl)amino]-1,3,5-triazine-2,4-diyl][(2,2,6,6-tetramethyl-4-piperidinyl)imino]-1,6-hexanediyl[(2,2,6,6-tetramethyl-4-piperidinyl) imino]] (CAS-No. 71878-19-8),

(i-29) tetrakis(1,2,2,6,6-pentamethyl-4-piperidyl) butane-1,2,3,4-tetracarboxylate (CAS-No. 91788-83-9),

or a mixture thereof,

(ii) 0 to 40 wt.% of a second polymer stabilizer, which is zinc stearate, calcium stearate, magnesium stearate or a mixture thereof,

(iii) 0 to 34 wt.% of a third polymer stabilizer, which is zinc oxide, hydrotalcite, sodium benzoate or a mixture thereof,

(iv) 0 to 20 wt.% of a further ingredient, which is different to the first polymer stabilizer, the second polymer stabilizer and the third polymer stabilizer,

wherein the sum of components (i), (ii), (iii) and (iv) is 100 wt.%,

wherein the tablet has a weight above 20 mg and below 330 mg and a cross-section dimension above 3 mm and below 18 mm.

10. A tablet according to claim 9, wherein the tablet has a geometric form, at which in case a corner is present, each corner possesses only angles directed to the inner side of the tablet above 90° or each corner is convexly rounded, and at which in case of an edge is present, each edge possesses only angles directed to the inner side of the tablet above 90° or each edge is convexly rounded, except in case a corner or an edge originates from an embossed groove.

11. A tablet according to claims 9 or 10, wherein the first polymer stabilizer is

(i-1) tris(2,4-ditert-butylphenyl) phosphite (CAS-No. 31570-04-4),

(i-4) tetrakis-[3-(3,5-ditert-butyl-4-hydroxy-phenyl)-propionyloxymethyl]methane (CAS-No. 6683-19-8),

(i-5) 3-(3,5-ditert-butyl-4-hydroxy-phenyl)-propionic acid stearyl ester (CAS-No. 2082-79-3),

(i-6) 3-(3,5-ditert-butyl-4-hydroxy-phenyl)-N-[6-[3-(3,5-ditert-butyl-4-hydroxy-phenyl)propanoylamino]hexyl]propanamide (CAS-No. 23128-74-7),

(i-7) 3-(3,5-ditert-butyl-4-hydroxyphenyl)-N'-[3-(3,5-ditert-butyl-4-hydroxyphenyl)-propanoyl]propanehydrazide (CAS-No. 32687-78-8),

(i-8) 2-[2-[2-[3-(3-tert-butyl-4-hydroxy-5-methyl-phenyl)propanoyloxy]ethoxy]ethoxy]ethyl 3-(3-tert-butyl-4-hydroxy-5-methyl-phenyl)propanoate (CAS-No. 36443-68-2),

(i-9) 4-[[3,5-bis[(3,5-ditert-butyl-4-hydroxy-phenyl)methyl]-2,4,6-trimethyl-phenyl]methyl]-2,6-ditert-butyl-phenol (CAS-No. 1709-70-2),

(i-10) 1,3,5-tris(3,5-ditert-butyl-4-hydroxybenzyl)-1,3,5-triazine-2,4,6(1H,3H,5H)-trione (CAS-No. 27676-62-6),

(i-12) N,N-dioctadecylhydroxylamine (CAS-No. 123250-74-8)

(i-13) dodecyl 3-(3-dodecoxy-3-oxo-propyl)sulfanylpropanoate (CAS-No. 123-28-4),

(i-14) octadecyl 3-(3-octadecoxy-3-oxo-propyl)sulfanylpropanoate (CAS-No. 693-36-7),

(i-16) bis(2,2,6,6-tetramethyl-4-piperidyl) decanedioate (CAS-No.52829-07-9),

or a mixture thereof.

12. A tablet according to claim 11, wherein the first polymer stabilizer is
    (i-1) tris(2,4-ditert-butylphenyl) phosphite (CAS-No. 31570-04-4),
    (i-4) tetrakis-[3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-propionyloxymethyl]methane (CAS-No. 6683-19-8),
    (i-5) 3-(3,5-ditert-butyl-4-hydroxy-phenyl)-propionic acid stearyl ester (CAS-No. 2082-79-3),
    (i-7) 3-(3,5-ditert-butyl-4-hydroxyphenyl)-N'-[3-(3,5-ditert-butyl-4-hydroxyphenyl)-propanoyl]propanehydrazide (CAS-No. 3268-78-8),
    (i-10) 1,3,5-tris(3,5-di-tert-butyl-4-hydroxybenzyl)-1,3,5-triazine-2,4,6(1H,3H,5H)-trione (CAS-No. 27676-62-6),
    (i-16) bis(2,2,6,6-tetramethyl-4-piperidyl) decanedioate (CAS-No.52829-07-9),
    or a mixture thereof.

13. A tablet according to any one of claims 9 to 12, wherein the further ingredient (iv) contains less than 3 wt.% of polymeric components, which are different to the first primary polymer stabilizers (i-22), (i-26), (i-27) and (i-28), based on the sum of components (i), (ii), (iii) and (iv), which is 100 wt.%.

14. A tablet according to any one of claims 9 to 13, wherein the further ingredient (iv) contains less than 9 wt.% of a binder, which is a molecule comprising an alkyl or alkenyl group with more than 14 carbon atoms and is different to the first primary polymer stabilizers (i-5), (i-12) and (i-14) and the secondary polymer stabilizers zinc stearate, calcium stearate and magnesium stearate, based on the sum of components (i), (ii), (iii) and (iv), which is 100 wt.%.

15. A tablet according to any one of claims 9 to 14, wherein the secondary polymer stabilizer (ii) is contained in an amount of 0 to 29 wt.% based on the sum of components (i), (ii), (iii) and (iv), which is 100 wt.%.

16. A tablet according to any one of claims 9 to 15, wherein the further ingredient (iv) is contained in an amount of 0 to 9 wt.% based on the sum of components (i), (ii), (iii) and (iv), which is 100 wt.%.

17. A tablet according to any one of claims 9 to 16, wherein the tablet has a weight above 55 mg and below 200 mg and a cross-section dimension above 4 mm and below 15 mm.

18. A method for manufacturing a stabilized polymer, which comprises the steps of
    (AP) dosing a tablet as defined in any one of claim 9 to 17 into a polymer to obtain a tablet-polymer mixture,

(BP) exposing the tablet-polymer mixture to a temperature in the range of 120 to 340°C under mechanical stirring to obtain a stabilized polymer,

wherein the polymer is a polyolefin, a polystyrene or a mixture thereof.

19. A method for manufacturing a stabilized polymer according to claim 18, wherein step (BP) takes place in an extruder or a co-kneader.

20. A method for manufacturing a stabilized polymer according to claims 18 or 19, wherein the polymer to which the tablet is dosed in step (AP) is present in the form of pellets.

21. A tablet-polymer mixture comprising the components

(a) a tablet as defined in any one of claims 9 to 17, and

(b) a polymer, which is a polyolefin, a polystyrene or a mixture thereof, wherein the polymer is in the form of pellets and the pellets have an average pellet weight above 20 mg and below 330 mg and an average pellet cross-section dimension above 3 mm and below 18 mm, and

wherein component (a) is contained in an amount from 0.01 wt.% to 5 wt.% based on the the amount of component (b).

22. The use of a tablet as defined in any one of claims 9 to 17 for a dust-free handling of its components at manufacturing of a stabilized polymer, wherein the polymer is a polyolefin, a polystyrene or a mixture thereof.